+1 |BT| (S1 (S (NP (NP (NN Hesperidin)) (, ,) (NP (NP (DT the) (ADJP (RBS most) (JJ important)) (NN _PROT1_)) (PP (IN of) (NP (NN Citrus) (CD sp.)))) (, ,)) (ADVP (RB significantly)) (VP (VP (VBZ increases) (NP (NN HDL))) (CC and) (VP (VBZ lowers) (NP (NP (NP (NN _PROT2_)) (, ,) (NP (NN LDL)) (, ,) (NP (JJ total) (NN lipid)) (CC and) (NP (NN triglyceride) (NN plasma) (NNS levels))) (PP (PP (IN in) (NP (JJ normolipidemic) (NNS rats))) (CC and) (PP (IN in) (NP (NP (NNS rats)) (PP (IN with) (NP (ADJP (ADJP (JJ diet-)) (CC and) (ADJP (JJ triton-induced))) (NN hyperlipidemia))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN hCG)) (, ,) (NP (NN hCG)) (CC plus) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))))) (PP (IN on) (NP (NP (NP (NP (LST (LS [3H) (-RRB- -RSB-)) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (NNS formations)) (PP (IN in) (NP (NP (NN porcine) (NN myometrial) (NNS cells)) (VP (VBN obtained) (PP (IN from) (NP (ADJP (ADJP (JJ ovariectomized)) (CC and) (ADJP (JJ cyclic))) (NNS gilts))))))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN hCG)) (, ,) (NP (NN hCG)) (CC plus) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_))))) (PP (IN on) (NP (NP (NP (NP (LST (LS [3H) (-RRB- -RSB-)) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (NNS formations)) (PP (IN in) (NP (NP (NN porcine) (NN myometrial) (NNS cells)) (VP (VBN obtained) (PP (IN from) (NP (ADJP (ADJP (JJ ovariectomized)) (CC and) (ADJP (JJ cyclic))) (NNS gilts))))))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN hCG)) (, ,) (NP (NN hCG)) (CC plus) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_))))) (PP (IN on) (NP (NP (NP (NP (LST (LS [3H) (-RRB- -RSB-)) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN IP)) (-RRB- -RRB-))) (NNS formations)) (PP (IN in) (NP (NP (NN porcine) (NN myometrial) (NNS cells)) (VP (VBN obtained) (PP (IN from) (NP (ADJP (ADJP (JJ ovariectomized)) (CC and) (ADJP (JJ cyclic))) (NNS gilts))))))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (JJS highest) (NN production)) (PP (IN of) (NP (NP (JJ total) (NN _PROT1_) (NNS _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN d.p.m.)) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN found) (PP (IN in) (NP (NP (NNS cells)) (PP (IN from) (NP (NP (JJ ovariectomized) (NNS gilts)) (VP (VP (VBN given) (NP (NP (ADJP (FW in) (FW vivo)) (NN estradiol) (NN benzoate)) (CC and) (NP (NN progesterone))) (PP (IN for) (NP (CD five) (JJ consecutive) (NNS days)))) (CC and) (VP (VBN treated) (PP (IN with) (NP (NP (NP (ADJP (CD 1000) (NN mU)) (NN hCG)) (CC and) (NP (ADJP (CD 100) (NN mU)) (NN hCG))) (CC plus) (NP (NP (ADJP (CD 1) (NN microM)) (NN _PROT2_)) (PRN (-LRB- -LRB-) (QP (QP (CD 984) (CC +/-) (CD 84) (CC and) (CD 1063)) (CC +/-) (QP (QP (CD 131) (CC vs) (CD 314) (CC +/-) (CD 36)) (, ,))) (ADVP (RB respectively)) (-RRB- -RRB-))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (EX There)) (VP (VBD was) (ADVP (RB also)) (NP (NP (DT a) (ADJP (RB very) (JJ significant)) (NN increase)) (PP (IN of) (NP (NN _PROT1_)))) (PP (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NP (CD 1000) (NN mU) (NN hCG)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ <) (CD 0.001)) (-RRB- -RRB-))) (CC and) (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (CD 1000) (NN mU)) (NN hCG)) (CC plus) (NP (NN _PROT_))) (VP (VBD were) (VP (VBN added) (PRN (-LRB- -LRB-) (S (NP (NN p) (NN <) (CD 0.001) (CC and) (NN p)) (VP (JJ <) (NP (CD 0.01)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))))) |ET|
-1 |BT| (S1 (S (NP (EX There)) (VP (VBD was) (ADVP (RB also)) (NP (NP (DT a) (ADJP (RB very) (JJ significant)) (NN increase)) (PP (IN of) (NP (NN _PROT1_)))) (PP (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NP (CD 1000) (NN mU) (NN hCG)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ <) (CD 0.001)) (-RRB- -RRB-))) (CC and) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (CD 1000) (NN mU)) (NN hCG)) (CC plus) (NP (NN _PROT_))) (VP (VBD were) (VP (VBN added) (PRN (-LRB- -LRB-) (S (NP (NN p) (NN <) (CD 0.001) (CC and) (NN p)) (VP (JJ <) (NP (CD 0.01)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))))) |ET|
+1 |BT| (S1 (S (NP (EX There)) (VP (VBD was) (ADVP (RB also)) (NP (NP (DT a) (ADJP (RB very) (JJ significant)) (NN increase)) (PP (IN of) (NP (NN _PROT1_)))) (PP (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NP (CD 1000) (NN mU) (NN hCG)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ <) (CD 0.001)) (-RRB- -RRB-))) (CC and) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (CD 1000) (NN mU)) (NN hCG)) (CC plus) (NP (NN _PROT2_))) (VP (VBD were) (VP (VBN added) (PRN (-LRB- -LRB-) (S (NP (NN p) (NN <) (CD 0.001) (CC and) (NN p)) (VP (JJ <) (NP (CD 0.01)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))))) |ET|
-1 |BT| (S1 (S (NP (EX There)) (VP (VBD was) (ADVP (RB also)) (NP (NP (DT a) (ADJP (RB very) (JJ significant)) (NN increase)) (PP (IN of) (NP (NN _PROT_)))) (PP (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NP (CD 1000) (NN mU) (NN hCG)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ <) (CD 0.001)) (-RRB- -RRB-))) (CC and) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (CD 1000) (NN mU)) (NN hCG)) (CC plus) (NP (NN _PROT_))) (VP (VBD were) (VP (VBN added) (PRN (-LRB- -LRB-) (S (NP (NN p) (NN <) (CD 0.001) (CC and) (NN p)) (VP (JJ <) (NP (CD 0.01)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))))) |ET|
+1 |BT| (S1 (S (NP (EX There)) (VP (VBD was) (ADVP (RB also)) (NP (NP (DT a) (ADJP (RB very) (JJ significant)) (NN increase)) (PP (IN of) (NP (NN _PROT_)))) (PP (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NP (CD 1000) (NN mU) (NN hCG)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ <) (CD 0.001)) (-RRB- -RRB-))) (CC and) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_))))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (CD 1000) (NN mU)) (NN hCG)) (CC plus) (NP (NN _PROT2_))) (VP (VBD were) (VP (VBN added) (PRN (-LRB- -LRB-) (S (NP (NN p) (NN <) (CD 0.001) (CC and) (NN p)) (VP (JJ <) (NP (CD 0.01)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))))) |ET|
+1 |BT| (S1 (S (NP (EX There)) (VP (VBD was) (ADVP (RB also)) (NP (NP (DT a) (ADJP (RB very) (JJ significant)) (NN increase)) (PP (IN of) (NP (NN _PROT_)))) (PP (IN after) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (NP (CD 1000) (NN mU) (NN hCG)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ <) (CD 0.001)) (-RRB- -RRB-))) (CC and) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_))))))) (SBAR (WHADVP (WRB when)) (S (NP (NP (ADJP (CD 1000) (NN mU)) (NN hCG)) (CC plus) (NP (NN _PROT2_))) (VP (VBD were) (VP (VBN added) (PRN (-LRB- -LRB-) (S (NP (NN p) (NN <) (CD 0.001) (CC and) (NN p)) (VP (JJ <) (NP (CD 0.01)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))))) |ET|
+1 |BT| (S1 (S (NP (RB Only) (NN _PROT1_)) (ADVP (RB alone)) (VP (VBD increased) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (NN _PROT2_)))) (PP (IN in) (NP (NP (NNS cells)) (PP (IN from) (NP (NP (JJ ovariectomized) (NNS pigs)) (VP (VBN treated) (PP (IN with) (NP (NN estradiol))) (ADVP (FW in) (FW vivo))))))) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.01)) (-RRB- -RRB-))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (DT The) (JJS highest) (NN dose)) (PP (IN of) (NP (NN hCG)))) (CC plus) (NP (NP (DT The) (JJS highest) (NN dose)) (PP (IN of) (NP (NP (NN hCG)) (CC plus) (NP (NN _PROT1_)))))) (VP (VBD provoked) (NP (NP (NN accumulation)) (PP (IN of) (NP (NN total) (LST (LS [3H) (-RRB- -RSB-)) (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-))) (NP (CD 53) (NN %))))) (PP (IN over) (NP (DT the) (JJ basal) (NN level))) (PP (IN on) (NP (NP (NNS days) (NP (CD 21/1))) (PP (IN of) (NP (DT the) (NN estrous) (NN cycle)))))))) |ET|
+1 |BT| (S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBZ demonstrates) (SBAR (IN that) (S (NP (NP (NN hCG)) (CC and) (NP (NN _PROT1_))) (VP (MD can) (VP (VB increase) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (JJ _PROT2_) (NNS _PROT2_))) (PP (IN in) (NP (NN porcine) (NN myometrial) (NNS cells))))))))))) |ET|
+1 |BT| (S1 (S (PP (IN In) (NP (NN HVSMC))) (S (S (NP (CC both) (NP (NN _PROT1_)) (CC and) (NP (NN AVP))) (VP (VBD increased) (NP (NP (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (NN production)) (CC and) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (NN response))))) (, ,) (CC but) (S (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT the) (NNS responses)))) (VP (VBD was) (ADJP (ADJP (JJR greater)) (PP (IN for) (NP (NN _PROT_))) (PP (IN than) (NP (NN AVP))))))))) |ET|
-1 |BT| (S1 (S (PP (IN In) (NP (NN HVSMC))) (S (S (NP (CC both) (NP (NN _PROT1_)) (CC and) (NP (NN AVP))) (VP (VBD increased) (NP (NP (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (NN production)) (CC and) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (NN response))))) (, ,) (CC but) (S (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT the) (NNS responses)))) (VP (VBD was) (ADJP (ADJP (JJR greater)) (PP (IN for) (NP (NN _PROT2_))) (PP (IN than) (NP (NN AVP))))))))) |ET|
-1 |BT| (S1 (S (PP (IN In) (NP (NN HVSMC))) (S (S (NP (CC both) (NP (NN _PROT_)) (CC and) (NP (NN AVP))) (VP (VBD increased) (NP (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN IP3)) (-RRB- -RRB-))) (NN production)) (CC and) (NP (NP (NN [Ca2+) (-RRB- -RSB-) (CD i)) (NN response))))) (, ,) (CC but) (S (NP (NP (DT the) (NN efficacy)) (PP (IN of) (NP (DT the) (NNS responses)))) (VP (VBD was) (ADJP (ADJP (JJR greater)) (PP (IN for) (NP (NN _PROT2_))) (PP (IN than) (NP (NN AVP))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (JJ Gamma-aminobutyric) (NN acid) (NN mediation)) (PP (IN of) (NP (NP (DT the) (JJ inhibitory) (NN effect)) (PP (IN of) (NP (JJ nitric) (NN oxide))) (PP (IN on) (NP (NP (DT the) (NP (NP (NN arginine) (NN vasopressin)) (CC and) (NP (NN _PROT1_))) (NNS responses)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia)))))))))) |ET|
+1 |BT| (S1 (S (NP (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (DT the) (NP (NP (JJ nitric) (NN oxide)) (PRN (-LRB- -LRB-) (NP (NN NO)) (-RRB- -RRB-))) (NN synthase) (NN inhibitor) (NN L-NAME)) (VP (VBZ exerts) (NP (JJ positive) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NP (NP (NP (NN arginine) (NN vasopressin)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-))) (CC and) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-)))) (NNS responses)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia))))) (, ,) (S (VP (VBG suggesting) (NP (NP (JJ inhibitory) (NNS actions)) (PP (IN of) (NP (NN NO))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NP (NP (NNP AVP)) (CC and) (NP (NNP _PROT1_))) (JJ secretory) (NNS patterns)) (PP (IN during) (NP (NP (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NP (NN 0.15) (NN IU/kg)) (, ,) (NP (NN i.v.))) (-RRB- -RRB-))) (NN -tolerance) (NNS tests)) (PRN (-LRB- -LRB-) (NP (NN ITT)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN examined) (PP (IN in) (NP (NP (CD seven) (JJ normal) (JJ male) (NNS subjects)) (PP (PP (IN with) (S (PRN (-LRB- -LRB-) (NP (JJ experimental) (NNS tests)) (-RRB- -RRB-)))) (CC and) (PP (IN without) (NP (NP (PRN (-LRB- -LRB-) (NP (NN control) (NN test)) (-RRB- -RRB-)) (NP (JJ concomitant) (NN treatment)) (PP (IN with) (NP (NP (NN L-NAME)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 40) (NNS micrograms/kg)) (VP (VBN injected))) (CC plus) (NP (NP (CD 50) (NNS micrograms/kg)) (VP (VBN infused)))) (, ,) (NP (NN i.v.)) (-RRB- -RRB-))))) (, ,) (NP (NP (DT the) (JJ GABAergic) (NN agent) (NN sodium) (NN valproate)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 600) (NN mg)) (PP (IN in) (NP (CD three) (JJ divided) (NNS doses)))) (ADVP (RB orally))) (-RRB- -RRB-))) (CC or) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN L-NAME)) (CC and) (NP (NN sodium) (NN valproate)))))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (JJ _PROT1_) (NN hypoglycemia)) (VP (VBN increased) (PP (IN by) (NP (NP (ADJP (ADJP (JJ 2-fold)) (PRN (-LRB- -LRB-) (NP (NP (NN peak)) (CC vs.) (NP (NN baseline))) (-RRB- -RRB-))) (NN plasma) (NN AVP)) (CC and) (NP (NN _PROT2_) (NNS levels)))))))) |ET|
+1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (NP (NP (NP (DT a) (JJ GABAergic) (NN mediation)) (PP (IN of) (NP (NP (DT the) (JJ inhibitory) (NN modulation)) (PP (IN by) (NP (NN NO))) (PP (IN of) (NP (DT the) (NN AVP)))))) (CC and) (NP (NP (JJ _PROT1_) (NNS responses)) (PP (TO to) (NP (JJ _PROT2_) (NN hypoglycemia)))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-))) (CC and) (NP (NP (NN vasopressin)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-)))) (VP (VP (VB stimulate) (NP (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN glucagon))) (NN release)) (PP (IN from) (NP (DT the) (NN pancreas))))) (, ,) (CC and) (VP (VB evoke) (NP (NP (NN _PROT_) (NN secretion)) (PP (IN from) (NP (NP (DT the) (NN rat) (NN insulinoma) (NN cell) (NN line)) (, ,) (NP (NN RINm5F))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-))) (CC and) (NP (NP (NN vasopressin)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-)))) (VP (VP (VB stimulate) (NP (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN glucagon))) (NN release)) (PP (IN from) (NP (DT the) (NN pancreas))))) (, ,) (CC and) (VP (VB evoke) (NP (NP (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NP (DT the) (NN rat) (NN insulinoma) (NN cell) (NN line)) (, ,) (NP (NN RINm5F))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NP (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-))) (CC and) (NP (NP (NN vasopressin)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-)))) (VP (VP (VB stimulate) (NP (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN glucagon))) (NN release)) (PP (IN from) (NP (DT the) (NN pancreas))))) (, ,) (CC and) (VP (VB evoke) (NP (NP (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NP (DT the) (NN rat) (NN insulinoma) (NN cell) (NN line)) (, ,) (NP (NN RINm5F))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NNS Effects)) (PP (IN of) (NP (NP (NN _PROT1_)) (, ,) (NP (NN arginine-vasopressin)) (CC and) (NP (NN lysine-vasopressin)))) (PP (IN on) (NP (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN glucagon))) (NN secretion)) (PP (IN in) (NP (NN sheep)))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NP (DT the) (JJ posterior-pituitary) (NNS peptides)) (NP (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN OT)) (-RRB- -RRB-))) (, ,) (NP (NP (NN arginine-vasopressin)) (PRN (-LRB- -LRB-) (NP (NN AVP)) (-RRB- -RRB-))) (CC and) (NP (NP (NN lysine-vasopressin)) (PRN (-LRB- -LRB-) (NP (NN LVP)) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN glucagon))) (NN secretion)))) (VP (VBD were) (VP (VBN examined) (PP (IN in) (NP (JJ adult) (NN sheep))))))) |ET|
+1 |BT| (S1 (S (S (NP (NP (DT The) (JJ maximal) (NN _PROT1_) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT2_)) (CC and) (NP (NN AVP)))))) (VP (VBD were) (ADJP (RB very) (JJ similar)))) (, ,) (CC but) (S (NP (NP (DT the) (NN threshold)) (CC and) (NP (NP (JJ maximal) (NNS doses)) (PP (IN of) (NP (NN AVP))) (PP (IN for) (S (VP (VBG increasing) (NP (NN plasma) (NN _PROT_))))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NN _PROT_)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (NP (DT The) (JJ maximal) (NN _PROT1_) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT_)) (CC and) (NP (NN AVP)))))) (VP (VBD were) (ADJP (RB very) (JJ similar)))) (, ,) (CC but) (S (NP (NP (DT the) (NN threshold)) (CC and) (NP (NP (JJ maximal) (NNS doses)) (PP (IN of) (NP (NN AVP))) (PP (IN for) (S (VP (VBG increasing) (NP (NN plasma) (NN _PROT2_))))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NN _PROT_)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (NP (DT The) (JJ maximal) (NN _PROT1_) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT_)) (CC and) (NP (NN AVP)))))) (VP (VBD were) (ADJP (RB very) (JJ similar)))) (, ,) (CC but) (S (NP (NP (DT the) (NN threshold)) (CC and) (NP (NP (JJ maximal) (NNS doses)) (PP (IN of) (NP (NN AVP))) (PP (IN for) (S (VP (VBG increasing) (NP (NN plasma) (NN _PROT_))))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NN _PROT2_)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (NP (DT The) (JJ maximal) (NN _PROT_) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT1_)) (CC and) (NP (NN AVP)))))) (VP (VBD were) (ADJP (RB very) (JJ similar)))) (, ,) (CC but) (S (NP (NP (DT the) (NN threshold)) (CC and) (NP (NP (JJ maximal) (NNS doses)) (PP (IN of) (NP (NN AVP))) (PP (IN for) (S (VP (VBG increasing) (NP (NN plasma) (NN _PROT2_))))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NN _PROT_)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (NP (DT The) (JJ maximal) (NN _PROT_) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT1_)) (CC and) (NP (NN AVP)))))) (VP (VBD were) (ADJP (RB very) (JJ similar)))) (, ,) (CC but) (S (NP (NP (DT the) (NN threshold)) (CC and) (NP (NP (JJ maximal) (NNS doses)) (PP (IN of) (NP (NN AVP))) (PP (IN for) (S (VP (VBG increasing) (NP (NN plasma) (NN _PROT_))))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NN _PROT2_)))))))))) |ET|
+1 |BT| (S1 (S (S (NP (NP (DT The) (JJ maximal) (NN _PROT_) (NNS responses)) (VP (VBN induced) (PP (IN by) (NP (NP (NN _PROT_)) (CC and) (NP (NN AVP)))))) (VP (VBD were) (ADJP (RB very) (JJ similar)))) (, ,) (CC but) (S (NP (NP (DT the) (NN threshold)) (CC and) (NP (NP (JJ maximal) (NNS doses)) (PP (IN of) (NP (NN AVP))) (PP (IN for) (S (VP (VBG increasing) (NP (NN plasma) (NN _PROT1_))))))) (VP (VBD were) (ADJP (ADJP (JJR higher)) (PP (IN than) (NP (NP (DT those)) (PP (IN of) (NP (NN _PROT2_)))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NN Interleukin-1) (NN beta)) (VP (VBZ inhibits) (NP (NP (NN _PROT1_) (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NN secretion))) (PP (IN at) (NP (NP (NNS sites)) (PP (ADVP (RB apart)) (IN from) (NP (NN KATP) (NN channel))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Surprisingly)) (, ,) (ADVP (RB however)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (NNS islets)) (VP (VBD were) (VP (VBN depolarized) (ADVP (RB directly)) (S (VP (VBG using) (NP (NP (DT either)) (PP (IN of) (NP (NP (CD two) (NNS agonists)) (, ,) (NP (NP (NP (NN glyburide)) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ does) (RB not) (VP (VB act) (PP (IN via) (NP (NP (NN generation)) (PP (IN of) (NP (NN purine) (NNS nucleotides))))))))) (-RRB- -RRB-)) (CC or) (NP (NP (ADJP (CD 40) (NN mM)) (NN K+)) (-LRB- -LRB-) (SBAR (WHNP (WDT which)) (S (VP (VBZ acts) (ADJP (JJ distal) (PP (TO to) (NP (NN KATP) (NN channel))))))) (-RRB- -RRB-)))))))))))) (, ,) (S (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (NN secretion)) (VP (VBD were) (ADVP (RB again)) (VP (VBN obliterated) (PP (IN by) (NP (NN IL-1) (NN beta)))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS data)) (PRN (-LRB- -LRB-) (ADVP (RB together)) (PP (IN with) (NP (DT the) (NN finding) (SBAR (IN that) (S (NP (NN IL-1) (NN beta)) (VP (VBD inhibited) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT1_) (NN release))))))) (-RRB- -RRB-)) (VP (VBP suggest) (SBAR (IN that) (S (, ,) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NP (PRP$ its) (NNS effects)) (PP (PP (IN on) (NP (NN ATP) (NN synthesis))) (CC and) (ADVP (RB thereby)) (PP (IN on) (NP (DT the) (NN KATP) (NN channel)))))))) (, ,) (NP (NN IL-1) (NN beta)) (VP (VBZ has) (NP (QP (IN at) (JJS least) (CD two)) (ADJP (ADJP (JJ undescribed)) (, ,) (ADJP (JJ distal))) (NNS effects)) (PP (TO to) (NP (NP (NN block)) (CC both) (NP (NN _PROT2_)) (CONJP (RB as) (RB well) (IN as)) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN exocytosis)))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NN Association)) (PP (IN of) (NP (DT the) (NN insulin) (NN receptor))) (PP (IN with) (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PLCgamma)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN 3T3-L1) (NNS adipocytes)))) (VP (VBZ suggests) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN _PROT2_))) (PP (IN in) (NP (NP (JJ metabolic) (NN signaling)) (PP (IN by) (NP (NN _PROT_))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NN Association)) (PP (IN of) (NP (DT the) (NN insulin) (NN receptor))) (PP (IN with) (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PLCgamma)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN 3T3-L1) (NNS adipocytes)))) (VP (VBZ suggests) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN _PROT_))) (PP (IN in) (NP (NP (JJ metabolic) (NN signaling)) (PP (IN by) (NP (NN _PROT2_))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN Association)) (PP (IN of) (NP (DT the) (NN insulin) (NN receptor))) (PP (IN with) (NP (NP (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN PLCgamma)) (-RRB- -RRB-)))) (PP (IN in) (NP (NN 3T3-L1) (NNS adipocytes)))) (VP (VBZ suggests) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN _PROT1_))) (PP (IN in) (NP (NP (JJ metabolic) (NN signaling)) (PP (IN by) (NP (NN _PROT2_))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (DT the) (NN IR)))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN _PROT2_)))) (, ,) (NP (NN U73122)) (, ,)) (CC or) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NP (NN SH2) (NN domain) (NN glutathione) (NN S-transferase)) (NN fusion) (NNS proteins)) (VP (VBN derived) (PP (IN from) (NP (NN _PROT_)))))))) (S (VP (TO to) (VP (VB block) (NP (JJ _PROT_) (NN GLUT4) (NN translocation)))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (DT the) (NN IR)))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN _PROT_)))) (, ,) (NP (NN U73122)) (, ,)) (CC or) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NP (NN SH2) (NN domain) (NN glutathione) (NN S-transferase)) (NN fusion) (NNS proteins)) (VP (VBN derived) (PP (IN from) (NP (NN _PROT2_)))))))) (S (VP (TO to) (VP (VB block) (NP (JJ _PROT_) (NN GLUT4) (NN translocation)))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (DT the) (NN IR)))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN _PROT_)))) (, ,) (NP (NN U73122)) (, ,)) (CC or) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NP (NN SH2) (NN domain) (NN glutathione) (NN S-transferase)) (NN fusion) (NNS proteins)) (VP (VBN derived) (PP (IN from) (NP (NN _PROT_)))))))) (S (VP (TO to) (VP (VB block) (NP (JJ _PROT2_) (NN GLUT4) (NN translocation)))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (DT the) (NN IR)))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN _PROT1_)))) (, ,) (NP (NN U73122)) (, ,)) (CC or) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NP (NN SH2) (NN domain) (NN glutathione) (NN S-transferase)) (NN fusion) (NNS proteins)) (VP (VBN derived) (PP (IN from) (NP (NN _PROT2_)))))))) (S (VP (TO to) (VP (VB block) (NP (JJ _PROT_) (NN GLUT4) (NN translocation)))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (DT the) (NN IR)))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN _PROT1_)))) (, ,) (NP (NN U73122)) (, ,)) (CC or) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NP (NN SH2) (NN domain) (NN glutathione) (NN S-transferase)) (NN fusion) (NNS proteins)) (VP (VBN derived) (PP (IN from) (NP (NN _PROT_)))))))) (S (VP (TO to) (VP (VB block) (NP (JJ _PROT2_) (NN GLUT4) (NN translocation)))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB determine) (NP (NP (DT the) (JJ functional) (NN significance)) (PP (IN of) (NP (NP (DT the) (NN interaction)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (DT the) (NN IR)))))))))) (, ,) (NP (PRP we)) (VP (VBD used) (NP (NP (NP (NP (DT a) (JJ specific) (NN inhibitor)) (PP (IN of) (NP (NN _PROT_)))) (, ,) (NP (NN U73122)) (, ,)) (CC or) (NP (NP (NN microinjection)) (PP (IN of) (NP (NP (NP (NN SH2) (NN domain) (NN glutathione) (NN S-transferase)) (NN fusion) (NNS proteins)) (VP (VBN derived) (PP (IN from) (NP (NN _PROT1_)))))))) (S (VP (TO to) (VP (VB block) (NP (JJ _PROT2_) (NN GLUT4) (NN translocation)))))))) |ET|
-1 |BT| (S1 (S (SBAR (IN Although) (S (NP (JJ osmotic) (NNS stimuli)) (VP (VBP cause) (NP (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NP (JJ nitric) (NN oxide) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN NOS)) (-RRB- -RRB-))) (NN activity)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NN synthesis)) (PP (IN of) (NP (NP (NN AVP)) (CC and) (NP (NN _PROT1_)))))) (PP (IN in) (NP (NP (NP (DT the) (NN paraventricular)) (PRN (-LRB- -LRB-) (NP (NN PVN)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ supraoptic) (NNS nuclei)) (PRN (-LRB- -LRB-) (NP (NN SON)) (-RRB- -RRB-)))))))) (, ,) (NP (PRP it)) (VP (VBZ is) (RB not) (VP (VBN known) (SBAR (IN whether) (S (NP (NP (NN NOS) (NN activity)) (PP (IN in) (NP (DT the) (NN hypothalamus)))) (VP (VBZ changes) (PP (IN in) (NP (NP (DT the) (JJ diabetic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP have) (NP (NN plasma) (NN hyperosmolality)) (PP (IN with) (NP (NP (NNS hyperglycaemia)) (VP (VBN caused) (PP (IN by) (NP (NN _PROT2_) (NN deficiency)))))))))))))))))) |ET|
+1 |BT| (S1 (S (PP (NP (CD Three) (NNS weeks)) (IN after) (NP (NP (NN administration)) (PP (IN of) (NP (NN STZ))))) (, ,) (NP (DT the) (JJ diabetic) (NNS rats)) (VP (VBD were) (ADVP (RB subcutaneously)) (VP (VBN treated) (PP (IN with) (NP (NN _PROT1_))) (PP (IN for) (NP (NP (CD 1) (NN week)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD resulted) (PP (IN in) (NP (NP (JJ significant) (NN suppression)) (PP (IN of) (NP (NP (DT the) (NN induction)) (PP (IN of) (NP (NP (NN nNOS)) (, ,) (NP (NN AVP)) (CC and) (NP (NN _PROT2_) (NN gene) (NN expression)))) (PP (IN in) (NP (DT the) (NP (NN PVN)) (CC and) (NP (NN SON))))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NN Downregulation)) (PP (IN of) (NP (NP (NN _PROT1_) (NN _PROT1_) (CD _PROT1_) (NN mRNA)) (PP (IN in) (NP (NP (NP (JJ white) (NN adipose) (NN tissue)) (CC and) (NP (NP (VBG _PROT2_) (NN _PROT2_) (CD _PROT2_)) (NN mRNA))) (PP (IN in) (NP (JJ skeletal) (NN muscle))))))) (PP (IN during) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (NN _PROT_) (NN treatment)))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN Downregulation)) (PP (IN of) (NP (NP (NN _PROT1_) (NN _PROT1_) (CD _PROT1_) (NN mRNA)) (PP (IN in) (NP (NP (NP (JJ white) (NN adipose) (NN tissue)) (CC and) (NP (NP (VBG _PROT_) (NN _PROT_) (CD _PROT_)) (NN mRNA))) (PP (IN in) (NP (JJ skeletal) (NN muscle))))))) (PP (IN during) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (NN _PROT2_) (NN treatment)))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN Downregulation)) (PP (IN of) (NP (NP (NN _PROT_) (NN _PROT_) (CD _PROT_) (NN mRNA)) (PP (IN in) (NP (NP (NP (JJ white) (NN adipose) (NN tissue)) (CC and) (NP (NP (VBG _PROT1_) (NN _PROT1_) (CD _PROT1_)) (NN mRNA))) (PP (IN in) (NP (JJ skeletal) (NN muscle))))))) (PP (IN during) (NP (NP (DT the) (JJ early) (NNS stages)) (PP (IN of) (NP (NN _PROT2_) (NN treatment)))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN _PROT1_)) (PP (IN by) (NP (NP (JJ intravenous) (CC or) (JJ intracerebroventricular) (NN infusion)) (PP (IN for) (NP (CD 5) (NN h)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NP (NP (NN _PROT2_) (NN mRNA)) (PP (IN in) (S (VP (VBD WAT))))) (PRN (-LRB- -LRB-) (NP (CD 47-52) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN _PROT_) (NN mRNA)) (PP (IN in) (NP (NN SM)))) (PRN (-LRB- -LRB-) (NP (CD 33-37) (NN %)) (-RRB- -RRB-))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN _PROT1_)) (PP (IN by) (NP (NP (JJ intravenous) (CC or) (JJ intracerebroventricular) (NN infusion)) (PP (IN for) (NP (CD 5) (NN h)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NP (NP (NN _PROT_) (NN mRNA)) (PP (IN in) (S (VP (VBD WAT))))) (PRN (-LRB- -LRB-) (NP (CD 47-52) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN _PROT2_) (NN mRNA)) (PP (IN in) (NP (NN SM)))) (PRN (-LRB- -LRB-) (NP (CD 33-37) (NN %)) (-RRB- -RRB-))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NN _PROT_)) (PP (IN by) (NP (NP (JJ intravenous) (CC or) (JJ intracerebroventricular) (NN infusion)) (PP (IN for) (NP (CD 5) (NN h)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NP (NP (NP (NN _PROT1_) (NN mRNA)) (PP (IN in) (S (VP (VBD WAT))))) (PRN (-LRB- -LRB-) (NP (CD 47-52) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (NN _PROT2_) (NN mRNA)) (PP (IN in) (NP (NN SM)))) (PRN (-LRB- -LRB-) (NP (CD 33-37) (NN %)) (-RRB- -RRB-))))))))))) |ET|
-1 |BT| (S1 (S (NP (NN Denervation)) (VP (VP (VBD suppressed) (NP (NP (NN mRNA) (NNS levels)) (PP (IN for) (NP (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN COX-IV)) (PRN (-LRB- -LRB-) (NP (CD 59) (NN %)) (-RRB- -RRB-))))))) (CC and) (VP (VBD eliminated) (NP (NP (DT the) (JJ acute) (NN response)) (PP (TO to) (NP (NN _PROT_))) (PP (IN in) (NP (NN SM)))))))) |ET|
-1 |BT| (S1 (S (NP (NN Denervation)) (VP (VP (VBD suppressed) (NP (NP (NN mRNA) (NNS levels)) (PP (IN for) (NP (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN COX-IV)) (PRN (-LRB- -LRB-) (NP (CD 59) (NN %)) (-RRB- -RRB-))))))) (CC and) (VP (VBD eliminated) (NP (NP (DT the) (JJ acute) (NN response)) (PP (TO to) (NP (NN _PROT2_))) (PP (IN in) (NP (NN SM)))))))) |ET|
-1 |BT| (S1 (S (NP (NN Denervation)) (VP (VP (VBD suppressed) (NP (NP (NN mRNA) (NNS levels)) (PP (IN for) (NP (NP (NP (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (CD 49) (NN %)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (CD 36) (NN %)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN COX-IV)) (PRN (-LRB- -LRB-) (NP (CD 59) (NN %)) (-RRB- -RRB-))))))) (CC and) (VP (VBD eliminated) (NP (NP (DT the) (JJ acute) (NN response)) (PP (TO to) (NP (NN _PROT2_))) (PP (IN in) (NP (NN SM)))))))) |ET|
+1 |BT| (S1 (S (ADVP (RB Furthermore)) (, ,) (NP (PRP$ our) (JJ 14C-acetate-labeling) (NNS studies)) (VP (VBD showed) (NP (NP (DT a) (ADJP (CD 50) (NN %)) (NN reduction)) (PP (IN in) (NP (NP (NN _PROT1_) (NN _PROT1_) (NN synthesis)) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (DT either) (NN _PROT2_))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD could) (VP (VB account) (PP (IN for) (NP (NP (DT the) (NN reduction)) (PP (IN in) (NP (NP (JJ net) (NN apoB) (NN secretion)) (VP (VBN caused) (PP (IN by) (NP (NP (NN incubation)) (PP (IN with) (NP (DT these) (NNS compounds)))))))))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (DT the) (JJ fluorinated) (NNS analogues)))) (VP (VBD were) (VP (VBN evaluated) (PP (IN on) (NP (NP (NP (NN inhibition)) (PP (IN of) (NP (NN cress) (JJ seed) (NN germination)))) (CC and) (NP (NP (NN inhibition)) (PP (IN of) (NP (NP (JJ _PROT1_) (NN _PROT2_) (NN induction)) (PP (IN in) (NP (NN embryoless) (NN barley) (NNS half-seeds)))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (-LRB- -LRB-) (NN 2E) (, ,) (NN 4E) (-RRB- -RRB-) (CD -2-Fluoro-5-)) (PRN (-LRB- -LRB-) (NP (NP (NN 1'-hydroxy-2) ('' ')) (, ,) (NP (CD 6) ('' ')) (, ,) (NP (NN 6'-trimethyl-2'-cyclohexen-1'-yl))) (-RRB- -RRB-))) (S (S (NP (NP (JJ -3-methyl-2,4-pentadienoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN 5b)) (-RRB- -RRB-))) (VP (VBD showed) (NP (JJ potent) (JJ inhibitory) (NN activity)) (PP (IN at) (NP (DT the) (JJ same) (NN level))) (PP (IN as) (NP (NP (NN ABA)) (PP (IN in) (NP (DT the) (NN cress) (JJ seed) (NN germination) (NN test))))))) (, ,) (CC and) (S (NP (NN 5b)) (ADVP (RB also)) (VP (VBD inhibited) (NP (JJ _PROT1_) (NN _PROT2_) (NN induction)) (PP (IN at) (NP (NP (QP (QP (QP (QP (CD 4) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (CC -) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (, ,) (CD 3)) (NNS times)) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN ABA)) (PRN (-LRB- -LRB-) (QP (QP (QP (CD 1) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (CC -) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (ADJP (CD 50) (NN %)) (NN inhibition)) (PP (IN of) (NP (NN _PROT_) (NN production)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NP (-LRB- -LRB-) (NN 2E) (, ,) (NN 4E) (-RRB- -RRB-) (CD -2-Fluoro-5-)) (PRN (-LRB- -LRB-) (NP (NP (NN 1'-hydroxy-2) ('' ')) (, ,) (NP (CD 6) ('' ')) (, ,) (NP (NN 6'-trimethyl-2'-cyclohexen-1'-yl))) (-RRB- -RRB-))) (S (S (NP (NP (JJ -3-methyl-2,4-pentadienoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN 5b)) (-RRB- -RRB-))) (VP (VBD showed) (NP (JJ potent) (JJ inhibitory) (NN activity)) (PP (IN at) (NP (DT the) (JJ same) (NN level))) (PP (IN as) (NP (NP (NN ABA)) (PP (IN in) (NP (DT the) (NN cress) (JJ seed) (NN germination) (NN test))))))) (, ,) (CC and) (S (NP (NN 5b)) (ADVP (RB also)) (VP (VBD inhibited) (NP (JJ _PROT1_) (NN _PROT_) (NN induction)) (PP (IN at) (NP (NP (QP (QP (QP (QP (CD 4) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (CC -) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (, ,) (CD 3)) (NNS times)) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN ABA)) (PRN (-LRB- -LRB-) (QP (QP (QP (CD 1) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (CC -) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (ADJP (CD 50) (NN %)) (NN inhibition)) (PP (IN of) (NP (NN _PROT2_) (NN production)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NP (-LRB- -LRB-) (NN 2E) (, ,) (NN 4E) (-RRB- -RRB-) (CD -2-Fluoro-5-)) (PRN (-LRB- -LRB-) (NP (NP (NN 1'-hydroxy-2) ('' ')) (, ,) (NP (CD 6) ('' ')) (, ,) (NP (NN 6'-trimethyl-2'-cyclohexen-1'-yl))) (-RRB- -RRB-))) (S (S (NP (NP (JJ -3-methyl-2,4-pentadienoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN 5b)) (-RRB- -RRB-))) (VP (VBD showed) (NP (JJ potent) (JJ inhibitory) (NN activity)) (PP (IN at) (NP (DT the) (JJ same) (NN level))) (PP (IN as) (NP (NP (NN ABA)) (PP (IN in) (NP (DT the) (NN cress) (JJ seed) (NN germination) (NN test))))))) (, ,) (CC and) (S (NP (NN 5b)) (ADVP (RB also)) (VP (VBD inhibited) (NP (JJ _PROT_) (NN _PROT1_) (NN induction)) (PP (IN at) (NP (NP (QP (QP (QP (QP (CD 4) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (CC -) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (, ,) (CD 3)) (NNS times)) (NP (NP (DT the) (NN concentration)) (PP (IN of) (NP (NP (NN ABA)) (PRN (-LRB- -LRB-) (QP (QP (QP (CD 1) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (CC -) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 6)) (-RRB- -RRB-))) (-RRB- -RRB-)))) (PP (IN for) (NP (NP (ADJP (CD 50) (NN %)) (NN inhibition)) (PP (IN of) (NP (NN _PROT2_) (NN production)))))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (NP (NN Isolation)) (CC and) (NP (NN characterization))) (PP (IN of) (NP (NP (NN gibbestatin) (NN B)) (, ,) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (JJ _PROT1_) (NN expression)) (PP (IN of) (NP (NN _PROT2_)))))) (, ,)))) (CC and) (NP (NP (NN gibbestatin) (NN C)) (PP (IN from) (NP (NNS streptomycetaes))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (PRN (-LRB- -LRB-) (QP (CD 1) (CC and) (CD 2)) (-RRB- -RRB-))) (NN mRNA) (NNS levels)) (VP (VBD were) (VP (VBN determined) (PP (IN by) (NP (NP (NP (JJ reverse) (NN transcription-polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (NN methodology))) (PP (IN in) (NP (NP (JJ adipose) (NN tissue)) (CC and) (NP (JJ gastrocnemius) (NN muscle)))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT A) (JJ negative) (NN correlation)) (PP (IN between) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN _PROT1_) (NN expression))))))) (VP (VBD was) (VP (VBN found) (PP (PP (IN in) (NP (JJ control) (NNS animals))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ cafeteria-fed) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ beta3-adrenergic) (NN compound)) (PP (IN in) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (NNS animals))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (NP (DT the) (VBN reported) (JJ statistical) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN obesity)) (CC and) (NP (NN Trecadrine) (NN administration))) (VP (VBN found) (PP (PP (IN for) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN muscle) (NN _PROT2_) (NN expression)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NN plasma) (NN _PROT_)))))))))))) (CC and) (VP (VBD WAT) (NP (NN _PROT_) (NN expression)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT A) (JJ negative) (NN correlation)) (PP (IN between) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN _PROT1_) (NN expression))))))) (VP (VBD was) (VP (VBN found) (PP (PP (IN in) (NP (JJ control) (NNS animals))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ cafeteria-fed) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ beta3-adrenergic) (NN compound)) (PP (IN in) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (NNS animals))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (NP (DT the) (VBN reported) (JJ statistical) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN obesity)) (CC and) (NP (NN Trecadrine) (NN administration))) (VP (VBN found) (PP (PP (IN for) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN muscle) (NN _PROT_) (NN expression)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NN plasma) (NN _PROT2_)))))))))))) (CC and) (VP (VBD WAT) (NP (NN _PROT_) (NN expression)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT A) (JJ negative) (NN correlation)) (PP (IN between) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN _PROT1_) (NN expression))))))) (VP (VBD was) (VP (VBN found) (PP (PP (IN in) (NP (JJ control) (NNS animals))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ cafeteria-fed) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ beta3-adrenergic) (NN compound)) (PP (IN in) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (NNS animals))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (NP (DT the) (VBN reported) (JJ statistical) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN obesity)) (CC and) (NP (NN Trecadrine) (NN administration))) (VP (VBN found) (PP (PP (IN for) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN muscle) (NN _PROT_) (NN expression)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NN plasma) (NN _PROT_)))))))))))) (CC and) (VP (VBD WAT) (NP (NN _PROT2_) (NN expression)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT A) (JJ negative) (NN correlation)) (PP (IN between) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN _PROT_) (NN expression))))))) (VP (VBD was) (VP (VBN found) (PP (PP (IN in) (NP (JJ control) (NNS animals))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ cafeteria-fed) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ beta3-adrenergic) (NN compound)) (PP (IN in) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (NNS animals))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (NP (DT the) (VBN reported) (JJ statistical) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN obesity)) (CC and) (NP (NN Trecadrine) (NN administration))) (VP (VBN found) (PP (PP (IN for) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN muscle) (NN _PROT1_) (NN expression)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NN plasma) (NN _PROT2_)))))))))))) (CC and) (VP (VBD WAT) (NP (NN _PROT_) (NN expression)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT A) (JJ negative) (NN correlation)) (PP (IN between) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN _PROT_) (NN expression))))))) (VP (VBD was) (VP (VBN found) (PP (PP (IN in) (NP (JJ control) (NNS animals))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ cafeteria-fed) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ beta3-adrenergic) (NN compound)) (PP (IN in) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (NNS animals))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (NP (DT the) (VBN reported) (JJ statistical) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN obesity)) (CC and) (NP (NN Trecadrine) (NN administration))) (VP (VBN found) (PP (PP (IN for) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN muscle) (NN _PROT1_) (NN expression)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NN plasma) (NN _PROT_)))))))))))) (CC and) (VP (VBD WAT) (NP (NN _PROT2_) (NN expression)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT A) (JJ negative) (NN correlation)) (PP (IN between) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN _PROT_) (NN expression))))))) (VP (VBD was) (VP (VBN found) (PP (PP (IN in) (NP (JJ control) (NNS animals))) (, ,) (CC but) (PP (RB not) (IN in) (NP (DT the) (JJ cafeteria-fed) (NNS groups))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT a) (JJ differential) (NN response)) (PP (TO to) (NP (NP (DT the) (JJ beta3-adrenergic) (NN compound)) (PP (IN in) (NP (ADJP (ADJP (JJ lean)) (CC and) (ADJP (JJ obese))) (NNS animals))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VP (VBZ is) (PP (IN in) (NP (NP (NN agreement)) (PP (IN with) (NP (NP (DT the) (VBN reported) (JJ statistical) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN obesity)) (CC and) (NP (NN Trecadrine) (NN administration))) (VP (VBN found) (PP (PP (IN for) (S (VP (VBD WAT) (NP (NP (CD O2) (NN consumption)) (CC and) (NP (NN muscle) (NN _PROT_) (NN expression)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN for) (NP (NN plasma) (NN _PROT1_)))))))))))) (CC and) (VP (VBD WAT) (NP (NN _PROT2_) (NN expression)))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT The) (NNS aims)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD were)) (: :) (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (S (S (VP (TO to) (VP (VB assess) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (JJ maternal) (NN undernutrition)) (PP (IN during) (NP (NN pregnancy))))) (PP (IN on) (NP (NP (JJ adult) (NN offspring)) (PP (IN with) (NP (NP (NN regard)) (PP (TO to) (NP (NP (NP (NN growth)) (, ,) (NP (NN body) (NN composition)) (CC and) (NP (NN plasma) (NNS levels))) (PP (IN of) (NP (NP (NN glucose)) (, ,) (NP (NN _PROT1_)) (CC and) (NP (NN corticosterone)))))))))))))) (, ,) (CC and) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (NN _PROT2_) (NN treatment)) (ADJP (JJ early) (PP (IN in) (NP (NN life))))) (VP (MD could) (VP (VB ameliorate) (NP (NP (DT the) (JJ adverse) (NNS effects)) (PP (IN of) (NP (NN food) (NN restriction)))) (PP (IN in) (NP (NN utero))))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NP (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PLC)) (-RRB- -RRB-))) (NN activity)) (VP (VBD was) (VP (VBN investigated) (PP (IN by) (NP (NP (NN stimulation)) (PP (IN of) (NP (NP (NN membrane) (NNS preparations)) (VP (VBN obtained) (PP (IN from) (NP (NP (NP (NP (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN beta-TC3)) (-RRB- -RRB-)) (: -)) (, ,) (NP (NP (NN somatostatin)) (PRN (-LRB- -LRB-) (NP (NN Rin) (NN 1027-B2)) (-RRB- -RRB-)) (: -)) (, ,) (CC and) (NP (NN glucagon))) (-LRB- -LRB-) (NN INR1-G9) (-RRB- -RRB-) (JJ -producing) (JJ pancreatic) (NN cell) (NNS lines)))))))) (S (VP (VBG using) (NP (NP (NP (DT the) (JJ non-hydrolyzable) (NN GTP) (NN analogue) (NN GTPgammaS)) (ADVP (RB alone))) (, ,) (NP (NP (DT the) (JJ C-terminal) (NN octapeptide) (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK-8)) (-RRB- -RRB-))) (, ,) (CC or) (NP (NN gastrin))))))))) |ET|
+1 |BT| (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (VBD was) (VP (VBN examined) (SBAR (IN whether) (S (NP (NP (NN stimulation)) (PP (IN of) (NP (NN Swiss) (NN 3T3) (NNS cells))) (PP (IN with) (NP (NN _PROT1_)))) (VP (VBZ causes) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NP (DT the) (JJ subcellular) (NN distribution)) (PP (IN of) (NP (NN EGF) (NNS receptors)))) (CC and) (NP (NN _PROT2_) (NN _PROT2_)))) (SBAR (WHNP (WDT that)) (S (VP (MD could) (ADVP (RB potentially)) (VP (VB explain) (NP (DT the) (VBN observed) (NP (NP (NN synergy)) (CC or) (NP (NN costimulation))))))))))))))) (. .))) |ET|
+1 |BT| (S1 (S (ADVP (RB However)) (, ,) (NP (CC both) (NP (NN EGF)) (CC and) (NP (NN _PROT1_))) (VP (VBD stimulated) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_))) (PP (IN at) (NP (DT the) (NN actin) (NN arc)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN EGF) (NN receptor)) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (JJ _PROT_) (VBN stimulated) (NNS cells)))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (ADVP (RB However)) (, ,) (NP (CC both) (NP (NN EGF)) (CC and) (NP (NN _PROT1_))) (VP (VBD stimulated) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NN _PROT_) (NN _PROT_))) (PP (IN at) (NP (DT the) (NN actin) (NN arc)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN EGF) (NN receptor)) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (JJ _PROT2_) (VBN stimulated) (NNS cells)))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (ADVP (RB However)) (, ,) (NP (CC both) (NP (NN EGF)) (CC and) (NP (NN _PROT_))) (VP (VBD stimulated) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_))) (PP (IN at) (NP (DT the) (NN actin) (NN arc)))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN EGF) (NN receptor)) (PP (IN in) (NP (NP (DT the) (NN case)) (PP (IN of) (NP (JJ _PROT2_) (VBN stimulated) (NNS cells)))))))))))) (. .))) |ET|
+1 |BT| (S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP it)) (VP (VBZ is) (VP (VBN suggested) (SBAR (IN that) (S (NP (NP (DT the) (JJ _PROT1_) (NN coclustering)) (PP (IN of) (NP (DT the) (NN EGF) (NN receptor))) (PP (IN with) (NP (NN _PROT2_) (NN _PROT2_))) (PP (IN at) (NP (DT the) (NN actin) (NN arc)))) (VP (MD may) (VP (VB allow) (PP (IN for) (NP (NP (JJR greater) (NN efficiency)) (PP (IN of) (NP (NN signal) (NN transduction)))))))))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT the) (NN synergy)) (VP (VBN observed) (PP (IN for) (NP (DT these) (CD two) (NNS hormones))) (PP (IN in) (NP (NP (NN stimulation)) (PP (IN of) (NP (NN DNA) (NN synthesis)))))))))))) (. .))) |ET|
+1 |BT| (S1 (S (PP (IN For) (NP (NN example))) (, ,) (NP (NN _PROT1_)) (VP (VBZ suppresses) (NP (NP (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (NN expression)) (PP (IN in) (NP (DT the) (NN arcuate) (NN nucleus))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NP (NN Plasma) (NN insulin)) (, ,) (NP (NN cholecystokinin)) (, ,) (NP (NN galanin)) (, ,) (NP (NN _PROT1_) (NN _PROT1_)) (CC and) (NP (NN _PROT2_) (NNS levels))) (PP (IN in) (NP (JJ obese) (NNS women))) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NN type) (CD 2) (NN diabetes) (NN mellitus))))))) |ET|
-1 |BT| (S1 (S (NP (JJ Experimental) (NNS studies)) (VP (VBD provided) (NP (NP (NNS evidences)) (SBAR (IN that) (S (NP (NP (NN _PROT1_)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-))) (, ,) (NP (NP (NN galanin)) (PRN (-LRB- -LRB-) (NP (NN GAL)) (-RRB- -RRB-))) (, ,) (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (CC and) (NP (NN insulin))) (VP (VBP are) (VP (VBN involved) (PP (IN in) (NP (JJ feeding) (NN behaviour))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NN Plasma) (NNS concentrations)) (PP (IN of) (NP (NP (NN FSH)) (, ,) (NP (NP (NN _PROT1_)) (, ,) (NP (NN CCK)) (, ,) (NP (NN GAL)) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN insulin)))))) (VP (VBD were) (VP (VBN determined) (S (VP (VBG using) (NP (JJ commercial) (NN RIA) (NNS kits)))))))) |ET|
-1 |BT| (S1 (S (NP (PRP$ Our) (NNS results)) (, ,) (PP (FW ie) (NP (NP (JJR higher) (JJ mean) (NN plasma) (NN _PROT1_) (NNS levels)) (PP (IN in) (NP (NP (JJ postmenopausal) (JJ diabetic) (NNS women)) (CC and) (NP (NP (JJ positive) (NN correlation)) (PP (IN of) (NP (NN CCK))) (PP (IN with) (NP (NP (NN _PROT2_)) (CC and) (NP (NN insulin))))))))) (, ,) (MD may) (VP (VBP suggest) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (DT these) (NNS neuropeptides))) (PP (IN in) (NP (NP (JJ metabolic) (NNS disorders)) (VP (VBG leading) (PP (TO to) (NP (NN type) (CD 2) (NN diabetes) (NN mellitus)))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Finally)) (, ,) (NP (JJ recent) (NNS evidences)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NNS melanocortins)) (VP (MD could) (VP (VB be) (VP (VBN involved) (PP (PP (IN in) (S (VP (VBG mediating) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN _PROT1_))))))) (, ,) (CC and) (PP (IN in) (S (VP (VBG controlling) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))))))))))))))))) |ET|
